Drug Profile
Giloralimab - AbbVie
Alternative Names: ABBV-927Latest Information Update: 21 Feb 2023
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Antigen presenting cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pancreatic cancer
- Phase I Solid tumours
- No development reported Squamous cell cancer
Most Recent Events
- 21 Feb 2023 Giloralimab is still in phase I trials for Solid tumour in USA (IV and Intratumoral) (NCT02988960) (Abbvie pipeline, February 2023)
- 21 Feb 2023 Giloralimab is still in phase I trials for Solid tumour in US and Israel (IV) (NCT03893955) (Abbvie pipeline, February 2023)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Squamous-cell-cancer(First-line therapy, Late-stage disease, Monotherapy, Newly diagnosed, Treatment-naive) in USA (Intratumoural, Injection)